Novo Nordisk AS (NOVO B):企業の財務・戦略的SWOT分析

◆英語タイトル:Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1349
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Novo Nordisk AS (NOVO B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company that discovers, develops and manufactures innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions including hemophilia, human growth hormone (HGH) disorders and obesity. The company’s portfolio includes pre-filled delivery systems for HGH, and insulin; glucagon hypokit; needles; cartridge; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. With subsidiaries in Europe, North America, Asia, Latin America, Africa, Middle East and Australia, the company markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS Key Recent Developments

Apr 02,2020: Coronavirus (COVID-19) resources available from Novo Nordisk in the US
Apr 01,2020: Others : Macromoltek Announces Computational De Novo Antibody Design Offering, Targeting COVID-19
Mar 31,2020: NNIT A/S: 6/2020 NNIT renews operations maintenance agreement with Novo Nordisk
Mar 26,2020: Resolutions from the Annual General Meeting of Novo Nordisk
Mar 23,2020: Others : Novo Nordisk A/S – Share repurchase programme

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Novo Nordisk AS – Key Facts
Novo Nordisk AS – Key Employees
Novo Nordisk AS – Key Employee Biographies
Novo Nordisk AS – Major Products and Services
Novo Nordisk AS – History
Novo Nordisk AS – Company Statement
Novo Nordisk AS – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Novo Nordisk AS – Business Description
Business Segment: Biopharmaceuticals
Overview
Performance
Business Segment: Diabetes and Obesity Care
Overview
Performance
Key Stats
Geographical Segment: International Operations
Target Markets
Performance
Geographical Segment: North America
Target Markets
Performance
R&D Overview
Novo Nordisk AS – Corporate Strategy
Novo Nordisk AS – SWOT Analysis
SWOT Analysis – Overview
Novo Nordisk AS – Strengths
Novo Nordisk AS – Weaknesses
Novo Nordisk AS – Opportunities
Novo Nordisk AS – Threats
Novo Nordisk AS – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novo Nordisk AS, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 02, 2020: Coronavirus (COVID-19) resources available from Novo Nordisk in the US
Mar 26, 2020: Resolutions from the Annual General Meeting of Novo Nordisk
Feb 21, 2020: Leaders from 24 companies in the US Pharmaceutical Supply Chain collaborate to submit the MediLedger DSCSA Pilot Project Final Report to the FDA, proposing blockchain for an interoperable track and trace system for US prescription drugs
Feb 20, 2020: New drug combination restores beta cell function in animal model: potential for diabetes remission
Feb 07, 2020: Novo Nordisk invests DKK 800 million in upgrading and expanding production facilities in Kalundborg
Feb 05, 2020: Novo Nordisk’s operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019
Jan 24, 2020: HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future
Dec 13, 2019: DTU receives grant for advanced research equipment
Nov 21, 2019: Bayer and Shionogi Europe to keynote Veeva Commercial & Medical Summit, Europe
Nov 20, 2019: Novo Nordisk and UNICEF announce new partnership to help prevent childhood overweight and obesity
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Novo Nordisk AS, Key Facts
Novo Nordisk AS, Key Employees
Novo Nordisk AS, Key Employee Biographies
Novo Nordisk AS, Major Products and Services
Novo Nordisk AS, History
Novo Nordisk AS, Subsidiaries
Novo Nordisk AS, Key Competitors
Novo Nordisk AS, Ratios based on current share price
Novo Nordisk AS, Annual Ratios
Novo Nordisk AS, Annual Ratios (Cont...1)
Novo Nordisk AS, Annual Ratios (Cont...2)
Novo Nordisk AS, Interim Ratios
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novo Nordisk AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Novo Nordisk AS, Performance Chart (2015 - 2019)
Novo Nordisk AS, Ratio Charts
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Novo Nordisk AS (NOVO B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ludwig Institute For Cancer Research Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Ludwig Institute for Cancer Research Ltd (LICR) is a non-profit organization that conducts cancer research and clinical trial programs. The organization carries out research in the areas of clinical trials, genomics, cell biology, immunology, neuroscience, signaling, therapeutics, stem cells …
  • XL-protein GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary XL-protein GmbH (XL-protein) is a biopharmaceutical company that develops second generation biopharmaceutical drugs. The company develops PASylation technology, designed to enable the biopharmaceuticals drug development with extended plasma half-life and enhanced action. It provides its tech …
  • KPC Pharmaceuticals Inc (600422)-製薬・医療分野:企業M&A・提携分析
    Summary KPC Pharmaceuticals Inc (KPC), formerly Kunming Pharmaceutical Corp, a subsidiary of Holley Group Co Ltd, is a manufacturer of botanical drugs and other pharmaceutical products. The company offers panax notoginseng, gastrodine, artemether and botanical drugs. It also offers drugs such as xue …
  • TripAdvisor Inc:企業のM&A・事業提携・投資動向
    TripAdvisor Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TripAdvisor Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • The Tokyo Star Bank Ltd:企業の戦略・SWOT・財務情報
    The Tokyo Star Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Tokyo Star Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • B. Braun Melsungen AG-製薬・医療分野:企業M&A・提携分析
    Summary B. Braun Melsungen AG (B. Braun) is a global health care company. It offers products and solutions for therapy fields and applications including acute dialysis, infusion therapy, apheresis, interventional vascular, diagnostics and treatment, cardio-thoracic surgery, laparoscopy, degenerative …
  • Lee’s Pharmaceutical Holdings Ltd (950):企業の財務・戦略的SWOT分析
    Summary Lee's Pharmaceutical Holdings Ltd (Lee's Pharmaceutical) is a biopharmaceutical company that offers development of novel therapies and contract research services. The company provides products in the treatment of disease areas such as urology, cardiovascular oncology, dermatology, hematology …
  • Pernod Ricard SA:企業の戦略・SWOT・財務分析
    Pernod Ricard SA - Strategy, SWOT and Corporate Finance Report Summary Pernod Ricard SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Actinium Pharmaceuticals Inc (ATNM):企業の財務・戦略的SWOT分析
    Summary Actinium Pharmaceuticals Inc (ATNM), formerly Cactus Ventures Inc is a biopharmaceutical company that provides development of cancer immunotherapies. The company provides pipeline products such as Iomab-B that is used for hematopoietic stem cells transplantation. It provides Iomab-B through …
  • Proxy Biomedical Ltd-医療機器分野:企業M&A・提携分析
    Summary Proxy Biomedical Ltd (PBL) is a medical device company that research, develops and manufactures biomaterials for medical implant products. The company’s products include composite mesh, flat sheet 2D and 3D mesh, hernia plugs, resorbable synthetic mesh, resorbable surgical mesh, specialty su …
  • Nippon Flour Mills Co Ltd (2001):企業の財務・戦略的SWOT分析
    Nippon Flour Mills Co Ltd (2001) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Lockheed Martin Australia Pty Ltd:企業の戦略・SWOT・財務情報
    Lockheed Martin Australia Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Australia Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • MIS Implants Technologies Ltd:医療機器:M&Aディール及び事業提携情報
    Summary MIS Implants Technologies Ltd (MIS) is a medical device company that offers advanced products and solutions for dental implantology treatment. The company offers products such as superstructures, dental implants, tools and kits, and solutions for oral restoration and health, among others. It …
  • CoreRx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CoreRx Inc (CoreRx) is a contract development manufacturing organization that provides a comprehensive range of drug development services. The company provides products portfolio such as oral, topical, liquids or parental, ophthalmic and combined medicines, among others. It provides a wide r …
  • Arden Partners Plc (ARDN):企業の財務・戦略的SWOT分析
    Summary Arden Partners Plc (Arden) is a multi-service stockbroker that provides a range of financial services to corporate and institutional clients. The company offers research, distribution, execution and corporate finance services. Its distribution services include providing unique trading though …
  • Formycon AG (FYB):企業の財務・戦略的SWOT分析
    Summary Formycon AG (Formycon) formerly Nanohale AG is a biopharmaceutical company that develops biosimilar drugs candidates. The company offers biopharmaceutical imitation products for global recovery. It provides four biosimilar products in pre-clinical and clinical testing phases. Formycon’s pipe …
  • Cinemark Holdings Inc (CNK):企業の財務・戦略的SWOT分析
    Cinemark Holdings Inc (CNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Babcock Power Inc:企業の戦略的SWOT分析
    Babcock Power Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • CytRx Corp (CYTR):製薬・医療:M&Aディール及び事業提携情報
    Summary CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product comprises of its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of …
  • The National Commercial Bank:企業の戦略・SWOT・財務情報
    The National Commercial Bank - Strategy, SWOT and Corporate Finance Report Summary The National Commercial Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆